Group items tagged

The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function. This FOA solicits development of new, more easily accessible tools, reagents, and technologies to facilitate identification, tracking, manipulation, and analysis of glycans with their biological binding partners and determine their functions.

The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function.

The National Institute on Drug Abuse (NIDA) intends to publish a series of Funding Opportunity Announcements (FOA) for Cooperative Agreements to solicit applications for a network of researchers collaborating across justice and community-based service settings to transform community-level responses to opioid misuse and opioid use disorder in justice-involved populations. Opioid misuse and opioid use disorder consequences exist at the intersection of health and justice systems. Improving the capacity of the justice system to respond to opioid crisis with evidence-based approaches that include the use of medications for OUD requires strong partnerships between justice systems and healthcare as well as other community based organizations. Supporting the development of these relationships and novel models of justice-healthcare and other community collaborations is a critical target in addressing the current opioid crisis. NIDA is interested in launching a network of investigators who can rapidly conduct research to address the opioid crisis in justice settings. A variety of research methods will be used, including clinical trials, implementation science research, policy evaluations and/or modeling approaches. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects. This FOA is expected to use a multicomponent cooperative agreement mechanism. The FOA is expected to be published in October 2018 with an expected application due date in December 2018.

The Human Cell Atlas (HCA) is a global effort to create a reference map of all cell types in the human body. It is an ambitious goal to generate a fundamental reference for biomedical research. The HCA was born out of advances in single cell biology that made it conceivable to collect extensive measurements that inform our understanding of cellular heterogeneity in health and disease. Due to the growth of the community, pace of technology, and interest from the international community, the project has gone from conceivable to feasible. The Chan Zuckerberg Initiative and the Helmsley Charitable Trust are pleased to announce continued support for the Human Cell Atlas by collaborating on two new funding mechanisms that the community can access through a single application portal. The Chan Zuckerberg Initiative seeks to continue the work of the HCA community with a focus on interdisciplinary work and collaboration through the formation of 3 year Seed Networks. The Helmsley Charitable Trust welcomes applications that will construct a detailed atlas of the human gut. CZI Seed Networks aim to solidify growth of the community and result in a first draft of several organs - there is no requirement for a gut component in CZI applications. Additionally, newly formed Networks are designed to catalyze partnership among the scientific community and the funding community so that we can work together toward a first draft of the HCA.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion FOAs listed above.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR ) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful , proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

The NIH Directors Pioneer Award supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative research towards the ultimate goal of enhancing human health. Individuals from diverse backgrounds are encouraged to apply. Applications in all topics, including, but not limited to, the behavioral, social, biomedical, applied, and formal sciences, relevant to the broad mission of NIH are welcome and may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigators research program or elsewhere. The NIH Directors Pioneer Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.

The Substance Abuse andMental Health Services Administration (SAMHSA), Center for Substance AbuseTreatment (CSAT), isaccepting applications for fiscal year (FY) 2019 Provider's Clinical SupportSystem - Universities (Short Title: PCSS-Universities) grants. The purpose of this program is toexpand/enhance access to medication-assisted treatment (MAT) services forpersons with an opioid use disorder (OUD) seeking or receiving MAT throughensuring the education and training of students in the medical, physicianassistant and nurse practitioner fields. This program's focus is to ensure students fulfill the trainingrequirements needed to obtain a DATA waiver to prescribe MAT in office-basedsettings. The desired outcomes include: 1) an increase in the number of individuals completing the trainingrequirements for the DATA waiver, 2) an increase the number of individuals witha DATA waiver, and 3) an ultimate increase in those prescribing.

Soil communities are commonly the most overlooked part of an ecosystem because they are cryptic and difficult to study. However, they are responsible for a disproportionate number of ecosystem functions, including carbon and nutrient cycling, soil fertility, soil stability and water retention. Understanding how these communities change based on land management activities is a first step in understanding how ecosystem function might change. The purpose of this project is to address the relationships among forest treatments (thinning and use of logging machinery) to impacts on soil abiotic parameters (soil compaction, bulk density, hydrology, organic matter and soil carbon and nitrogen) on important soil groups (nematodes, microarthropods, bacteria, and fungi). Each of these groups is responsible for different functions, and can provide different information on the health of the soil, and therefore the ecosystem. With the current task agreement, we propose to look at the effects of mechanical thinning on these parameters in two ways across four different forest types (ponderosa pine, xeric mixed conifer, mesic mixed conifer and aspen). In both experiments, we will measure soil bulk density, soil compaction, soil hydraulic conductivity, water infiltration rate, soil organic matter and total C and N. We will use a mix of traditional microscopy and molecular methods to quantify the abundance and diversity of bacteria, fungi, nematodes and microarthropods.

The Division of Mathematical Sciences (DMS) in the Directorate for Mathematical and Physical Sciences (MPS) at the National Science Foundation (NSF) and the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH) plan to support research in mathematics and statistics on questions in the biological and biomedical sciences. Both agencies recognize the need for promoting research at the interface between the mathematical sciences and the life sciences. This program is designed to encourage new collaborations, as well as to support existing ones.

The Division of Mathematical Sciences (DMS)in the Directorate for Mathematical and Physical Sciences (MPS) at the National Science Foundation (NSF)and the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH)plan to support research in mathematics and statistics on questions in the biological and biomedical sciences. Both agencies recognize the need for promoting research at the interface between the mathematical sciences and the life sciences. This program is designed to encourage new collaborations, as well as to support existing ones.

The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics.

The Muscular Dystrophy Association is the world's leading nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, amyotrophic lateral sclerosis (ALS), and other neuromuscular diseases. It advances this mission by funding research; providing comprehensive healthcare services and support to MDA families nationwide; and rallying communities to fight back through advocacy, fundraising, and local engagement.

to request research applications that test innovative approaches to improve diabetes and obesity prevention and/or treatment in healthcare settings where individuals receive their medical care?. Research applications should be designed to test practical and sustainable strategies to improve processes of care and health outcomes for individuals with or at risk of diabetes and/or obesity. The research should also focus on approaches with the potential to be broadly disseminated outside the specific setting where it is being tested. The goal of the research is to obtain results that will improve healthcare practice and inform healthcare policy for the prevention or management of these conditions

This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, and hematology. Additional information concerning programmatic areas at NIDDK is available a www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx and applicants are strongly encouraged to discuss research priorities with the Scientific Contact.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NHLBI R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce in the mission areas of importance to NHLBI. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences

The National Science Foundation (NSF), through the Directorate for Engineering, the Directorate of Computer and Information Science and Engineering Division of Computer and Network Systems, and the Directorate for Mathematical and Physical Sciences Division of Materials Research, along with the U.S. Food and Drug Administration (FDA), through its Center for Devices and Radiological Health (CDRH), have established the NSF/FDA Scholar-in-Residence Program at FDA. This program comprises an interagency partnership for the investigation of scientific and engineering issues concerning emerging trends in medical device technology. This partnership is designed to enable investigators in science, engineering, and computer science to develop research collaborations within the intramural research environment at the FDA. This solicitation features three flexible mechanisms for support of research at the FDA: 1) Principal Investigators at FDA; 2) Postdoctoral Researchers at FDA; and 3) Graduate Students at FDA.

The Edward N. & Della L. Thome Memorial Foundation was created in 2002 to advance the health of older adults through the support of direct service projects and medical research on diseases and disorders affecting older adults. In keeping with the Foundation's mission, the goal of the Awards Program is to support translational research that will lead to improved therapies for individuals suffering from age- related macular degeneration (AMD)